Phase Ib/II study of safety and efficacy of low‐dose decitabine‐primed chemoimmunotherapy in patients with drug‐resistant relapsed/refractory alimentary tract cancer

International Journal of Cancer, EarlyView.


https://ift.tt/2HsHq28